| [1] |
Chebib FT， Hanna C， Harris PC，et al.Autosomal dominant polycystic kidney disease：a review[J]. JAMA， 2025， 333(19)：1708-1719.DOI： 10.1001/jama.2025.0310.
|
| [2] |
Suarez M， Titan S， Dahl NK.Autosomal dominant polycystic kidney disease[J]. Adv Kidney Dis Health， 2024， 31(6)：496-503.DOI： 10.1053/j.akdh.2024.07.003.
|
| [3] |
Torres VE， Ahn C， Barten T，et al.KDIGO 2025 clinical practice guideline for the evaluation，management，and treatment of autosomal dominant polycystic kidney disease (ADPKD)：executive summary[J]. Kidney Int， 2025， 107(2)：234-254.DOI： 10.1016/j.kint.2024.07.010.
|
| [4] |
Qiu J， Germino GG， Menezes LF.Mechanisms of cyst development in polycystic kidney disease[J]. Adv Kidney Dis Health， 2023， 30(3)：209-219.DOI： 10.1053/j.akdh.2023.03.001.
|
| [5] |
Sussman CR， Wang X， Chebib FT，et al.Modulation of polycystic kidney disease by G-protein coupled receptors and cyclic AMP signaling[J]. Cell Signal， 2020(72)：109649.DOI： 10.1016/j.cellsig.2020.109649.
|
| [6] |
Scholz JK， Kraus A， Lüder D，et al.Loss of Polycystin-1 causes cAMP-dependent switch from tubule to cyst formation[J]. iScience， 2022， 25(6)：104359.DOI： 10.1016/j.isci.2022.104359.
|
| [7] |
Hansen JN， Kaiser F， Leyendecker P，et al.A cAMP signalosome in primary cilia drives gene expression and kidney cyst formation[J]. EMBO Rep， 2022， 23(8)：e54315.DOI： 10.15252/embr.202154315.
|
| [8] |
Xu Y， Kuppe C， Perales-Patón J, et al. Adult human kidney organoids originate from CD24(＋) cells and represent an advanced model for adult polycystic kidney disease[J]. Nat Genet， 2022， 54(11)：1690-1701.DOI： 10.1038/s41588-022-01202-z.
|
| [9] |
Song A， Zhang C， Meng X．Mechanism and application of metformin in kidney diseases：an update[J]. Biomed Pharmacother， 2021(138)：111454.DOI： 10.1016/j.biopha.2021.111454.
|
| [10] |
Liu M， Zhang C， Gong X，et al.Kidney organoid models reveal cilium-autophagy metabolic axis as a therapeutic target for PKD both in vitro and in vivo[J]. Cell Stem Cell， 2024， 31(1)：52-70.e8.DOI： 10.1016/j.stem.2023.12.003.
|
| [11] |
Zhang Y， Daniel EA， Metcalf J，et al.CaMK4 overexpression in polycystic kidney disease promotes mTOR-mediated cell proliferation[J]. J Mol Cell Biol， 2022， 14(7)：mjac050.DOI： 10.1093/jmcb/mjac050.
|
| [12] |
Remadevi V， Jamadar A， Varghese MM，et al.Pirfenidone treatment attenuates fibrosis in autosomal dominant polycystic kidney disease[J]. bioRxiv， 2025：2025.08.25.672225.DOI： 10.1101/2025.08.25.672225.
|
| [13] |
|
| [14] |
Wu J， Cheng S， Lee G，et al.STING promotes the progression of ADPKD by regulating mitochondrial function，inflammation，fibrosis，and apoptosis[J]. Biomolecules， 2024， 14(10)：1215.DOI： 10.3390/biom14101215.
|
| [15] |
Zhou JX， Cheng AS， Chen L，et al.CD74 promotes cyst growth and renal fibrosis in autosomal dominant polycystic kidney disease[J]. Cells， 2024， 13(6)：489.DOI： 10.3390/cells13060489.
|
| [16] |
Lv J, Lan B, Fu L, et al. EZH2 inhibition or genetic ablation suppresses cyst growth in autosomal dominant polycystic kidney disease[J]. J Transl Med， 2024， 22(1)：979.DOI： 10.1186/s12967-024-05785-5.
|
| [17] |
Lee EJ， Seo E， Kim JW，et al.TAZ/Wnt-β-catenin/c-MYC axis regulates cystogenesis in polycystic kidney disease[J]. Proc Natl Acad Sci U S A， 2020， 117(46)：29001-29012.DOI： 10.1073/pnas.2009334117.
|
| [18] |
Zhang X， Li LX， Ding H，et al.Ferroptosis promotes cyst growth in autosomal dominant polycystic kidney disease mouse models[J]. J Am Soc Nephrol， 2021， 32(11)：2759-2776.DOI： 10.1681/ASN.2021040460.
|
| [19] |
Odedra D， Sabongui S， Khalili K，et al.Autosomal dominant polycystic kidney disease：role of imaging in diagnosis and management[J]. Radiographics， 2023， 43(1)：e220126.DOI： 10.1148/rg.220126.
|
| [20] |
|
| [21] |
Nigro E， Amicone M， D'Arco D，et al. Molecular diagnosis and identification of novel pathogenic variants in a large cohort of Italian patients affected by polycystic kidney diseases[J]. Genes (Basel)， 2023， 14(6)：1236.DOI： 10.3390/genes14061236.
|
| [22] |
Pei Y， Obaji J， Dupuis A，et al.Unified criteria for ultrasonographic diagnosis of ADPKD[J]. J Am Soc Nephrol， 2009， 20(1)：205-212.DOI： 10.1681/asn.2008050507.
|
| [23] |
|
| [24] |
Pei Y， Hwang Y H， Conklin J，et al.Imaging-based diagnosis of autosomal dominant polycystic kidney disease[J]. J Am Soc Nephrol， 2015， 26(3)：746-753.DOI： 10.1681/asn.2014030297.
|
| [25] |
Schönauer R， Baatz S， Nemitz-Kliemchen M，et al.Matching clinical and genetic diagnoses in autosomal dominant polycystic kidney disease reveals novel phenocopies and potential candidate genes[J]. Genet Med， 2020， 22(8)：1374-1383.DOI： 10.1038/s41436-020-0816-3.
|
| [26] |
Orisio S， Noris M， Rigoldi M，et al.Mutation analysis of PKD1 and PKD2 genes in a large italian cohort reveals novel pathogenic variants including a novel complex rearrangement[J]. Nephron， 2024， 148(5)：273-291.DOI： 10.1159/000530657.
|
| [27] |
Bleyer AJ， Westemeyer M， Xie J，et al.Genetic etiologies for chronic kidney disease revealed through next-generation renal gene panel[J]. Am J Nephrol， 2022， 53(4)：297-306.DOI： 10.1159/000522226.
|
| [28] |
Sun Q， Xu P， Mao A，et al.Targeted long-read sequencing enables higher diagnostic yield of ADPKD by accurate PKD1 genetic analysis[J]. NPJ Genom Med， 2025， 10(1)：22.DOI： 10.1038/s41525-025-00477-5.
|
| [29] |
|
| [30] |
Bais T， Geertsema P， Knol M，et al.Validation of the mayo imaging classification system for predicting kidney outcomes in ADPKD[J]. Clin J Am Soc Nephrol， 2024， 19(5)：591-601.DOI： 10.2215/CJN.0000000000000427.
|
| [31] |
Bais T， Knol M， Xue L，et al.Predicting kidney outcomes in autosomal dominant polycystic kidney disease：a comprehensive biomarker analysis[J]. Clin J Am Soc Nephrol， 2025， 20(5)：608-618.DOI： 10.2215/CJN.0000000680.
|
| [32] |
van Luijk F， Gansevoort RT， Blokzijl H，et al.Multidisciplinary management of chronic refractory pain in autosomal dominant polycystic kidney disease[J]. Nephrol Dial Transplant， 2023， 38(3)：618-629.DOI： 10.1093/ndt/gfac158.
|
| [33] |
Nowak KL， Hopp K．Metabolic reprogramming in autosomal dominant polycystic kidney disease：evidence and therapeutic potential[J]. Clin J Am Soc Nephrol， 2020， 15(4)：577-584.DOI： 10.2215/CJN.13291019.
|
| [34] |
Capelli I， Lerario S， Aiello V, et al. Diet and physical activity in adult dominant polycystic kidney disease：a review of the literature[J]. Nutrients， 2023， 15(11)：2621.DOI： 10.3390/nu15112621.
|
| [35] |
Brioni E, Villa G, Manara DF, et al. The educational aspect in promoting a low-sodium diet，physical activity and therapy adherence among patients with autosomal dominant polycystic disease：a literature review[J].G Ital Nefrol，2023，40(5)：2023-vol5.
|
| [36] |
Kidney Disease：Improving Global Outcomes(KDIGO) Blood Pressure Work Group.KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease[J]. Kidney Int， 2021， 99(3S)：S1-S87.DOI： 10.1016/j.kint.2020.11.003. |
| [37] |
Muensterman E， Torres JA， Weimbs T．Real-world outcomes of managing autosomal-dominant polycystic kidney disease using a medical food as part of a nutrition and lifestyle program to improve renal and metabolic health[J]. Front Nutr， 2025(12)：1624639.DOI： 10.3389/fnut.2025.1624639.
|
| [38] |
de Chickera S， Alam A．Dialysis and transplant considerations in autosomal dominant polycystic kidney disease[J]. Adv Kidney Dis Health， 2023， 30(5)：461-467.DOI： 10.1053/j.akdh.2023.06.005.
|
| [39] |
Geertsema P， Bais T， Kuiken V，et al.The long-term effect of tolvaptan treatment on kidney function and volume in patients with ADPKD[J]. Nephrol Dial Transplant， 2025， 40(9)：1764-1774.DOI： 10.1093/ndt/gfaf048.
|
| [40] |
Betts KA， Nunna S， Kumar R，et al.Tolvaptan and number needed to harm in autosomal dominant polycystic kidney disease[J]. Kidney Med， 2024， 6(4)：100802.DOI： 10.1016/j.xkme.2024.100802.
|
| [41] |
Stanley IK， Palma AM， Viecelli AK，et al.A secondary analysis of concurrent use of metformin and tolvaptan in ADPKD tolvaptan trials[J]. J Nephrol， 2024， 37(5)：1417-1419.DOI： 10.1007/s40620-024-01906-x.
|
| [42] |
Ong A， Gansevoort RT.TAMEing ADPKD with metformin：safe and effective？[J]. Kidney Int， 2021， 100(3)：513-515.DOI： 10.1016/j.kint.2021.07.021.
|
| [43] |
Su L， Yuan H， Zhang H，et al.PF-06409577 inhibits renal cyst progression by concurrently inhibiting the mTOR pathway and CFTR channel activity[J]. FEBS Open Bio， 2022， 12(10)：1761-1770.DOI： 10.1002/2211-5463.13459.
|
| [44] |
Gulieva RE， Ahmadvand P， Freedman BS.A novel rapalog shows improved safety vs.efficacy in a human organoid model of polycystic kidney disease[J]. Stem Cell Reports， 2025， 20(2)：102395.DOI： 10.1016/j.stemcr.2024.102395.
|
| [45] |
Bou Antoun MT， Borghol AH， Souvalian L，et al.Sodium-glucose cotransporter 2 inhibitors in autosomal dominant polycystic kidney disease：mechanistic insights and therapeutic promise[J]. J Am Soc Nephrol， 2026， 37(4)：861-880.DOI： 10.1681/ASN.0000000943.
|
| [46] |
Cebotaru L， Liu Q， Yanda MK，et al.Inhibition of histone deacetylase 6 activity reduces cyst growth in polycystic kidney disease[J]. Kidney Int， 2016， 90(1)：90-99.DOI： 10.1016/j.kint.2016.01.026.
|
| [47] |
Chen X, Yu C, Hou X, et al. Histone deacetylase 6 inhibition mitigates renal fibrosis by suppressing TGF-β and EGFR signaling pathways in obstructive nephropathy[J]. Am J Physiol Renal Physiol， 2020， 319(6)：F1003-F1014.DOI： 10.1152/ajprenal.00261.2020.
|
| [48] |
Cao X， Fan Z， Xu L，et al.Benzothiazole derivatives as histone deacetylase inhibitors for the treatment of autosomal dominant polycystic kidney disease[J]. Eur J Med Chem， 2024(271)：116428.DOI： 10.1016/j.ejmech.2024.116428.
|
| [49] |
Sun Y， Zou Q， Yu H，et al.Melanin-like nanoparticles slow cyst growth in ADPKD by dual inhibition of oxidative stress and CREB[J]. EMBO Mol Med， 2025， 17(1)：169-192.DOI： 10.1038/s44321-024-00167-2.
|
| [50] |
Lee E ， Valencia T M ， Varrone F ，et al.Discovery of next-generation anti-miR-17 oligonucleotide RGLS8429 for treatment of autosomal dominant polycystic kidney disease (ADPKD)：TH-PO408 [J]. J Am Soc Nephrol， 2022， 33(11S)：160.DOI： 10.1681/ASN.20223311S1160c.
|
| [51] |
Bais T， Gansevoort RT， Meijer E．Drugs in clinical development to treat autosomal dominant polycystic kidney disease[J]. Drugs， 2022， 82(10)：1095-1115.DOI： 10.1007/s40265-022-01745-9.
|
| [52] |
|
| [53] |
Zhou C， Mei C， Xue C．Preimplantation genetic diagnosis of autosomal dominant polycystic kidney disease applied in China[J]. Am J Kidney Dis， 2018， 72(5)：767.DOI： 10.1053/j.ajkd.2018.04.017.
|
| [54] |
Liu D， Cheng F， Pan S，et al.Stem cells：a potential treatment option for kidney diseases[J]. Stem Cell Res Ther， 2020， 11(1)：249.DOI： 10.1186/s13287-020-01751-2.
|
| [55] |
Wang J, Lin Y, Chen X, et al. Mesenchymal stem cells：a new therapeutic tool for chronic kidney disease[J]. Front Cell Dev Biol， 2022(10)：910592.DOI： 10.3389/fcell.2022.910592.
|